Zai Lab Selects ENPICOM’s IGX Platform to Leverage New NGS-powered Antibody Discovery Workflows

Zai Lab will use ENPICOM’s Antibody Discovery Module to expand its pipeline of innovative drugs and discover new therapeutic candidates

‘S-HERTOGENBOSCH, The Netherlands, May 27, 2021 / B3C newswire / -- ENPICOM, an innovative bioinformatics software engineering company, announced today that Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative, research-based, commercial-stage biopharmaceutical company based in China and the U.S., has signed a subscription agreement for ENPICOM’s IGX Platform. The IGX Platform with its Antibody Discovery Module (ADM) is a software platform engineered to assist researchers in diversifying and improving their candidate pools by selecting genetic sequences relating to a set of desired therapeutic characteristics from a database of millions of such sequences. Zai Lab intends to implement Next Generation Sequencing (NGS) as an additional technology to optimize its antibody selection.

“Zai Lab is a leader in innovative drug discovery and development in China, conducting many discovery, preclinical, and clinical programs around the world. We are delighted to provide them with the IGX Platform to optimize their antibody discovery workflow and to accelerate the development of innovative drugs,” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM.

Enabling targeted and efficient candidate selection with integrated bulk NGS, single cell sequencing and Sanger data analysis

Efficient analysis of NGS data provides a more targeted and streamlined selection of antibodies to express and analyze in the lab. This results in more diversified candidate pools and identification of candidates with improved characteristics. The analysis of both Sanger and NGS data together for antibody discovery requires specialized software that provides:

• Bulk NGS raw data quality control capabilities;
• Robust data management functionalities, including flexible and granular metadata annotation options;
• Analysis of high-level repertoire characteristics to determine the immunological competency of diverse animal models;
• Integrated bulk NGS, single cell, and Sanger data analyses for optimal antibody candidate selection;
• A user-friendly solution for sequence clustering, guided cluster selection, and phylogenetic analysis.

ENPICOM's IGX Platform with ADM fulfills these requirements and provides a versatile system to expand and diversify the candidate pool and select better antibodies more efficiently.

About ENPICOM
ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 25 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. In collaboration with DDL Diagnostic Laboratory, ENPICOM delivers full immune repertoire sequencing and analysis service.
For more information, visit enpicom.com and follow us on LinkedIn.

Contact

ENPICOM BV
Svitlana Lozova
Marketing Communications Manager
s.lozova@enpicom.com
+31 85 250 0575

Keywords: Sequence Analysis; High-Throughput Nucleotide Sequencing; Computational Biology; Data Analysis; Data Management; Software; Databases, Factual; Drug Discovery; Antibodies, Monoclonal; Pharmaceutical Preparations; Biotechnology; Netherlands;

Published by B3C newswire